Wire · regulatory
Grail rallies as FDA staff flags no major concerns for multi-cancer test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
The US FDA staff reviewers found no major concerns regarding the accuracy and safety of Grail's Galleri multi-cancer blood test, boosting the company's shares by 35%. The test is under review for premarket approval, which would ensure wider distribution and insurance coverage.
This Wire brief sits within Fusion42's coverage of Diagnostics, and 10 sources have reported it between 21 Sep 2026 and 3 Oct 2026.
◆ ◆ The Wire takeaway
You face a new opportunity as the FDA prepares to approve Galleri, creating routes for insurance coverage and routine use that could shift cancer screening protocols. Now is the time to connect with early adopters before the test becomes standard practice.
◆ Coverage
10 sources · first reported 21 Sep 2026 · latest 3 Oct 2026
◆ Related on Wire
◆ Topics